Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 3 1Phase 2 1

Status

Recruiting 36Active not recruiting 23Completed 18Terminated 10Withdrawn 5Not yet recruiting 5Unknown 3Approved for marketing 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5CNS 1

Conditions

Breast Neoplasms 5Solid Tumor 1Prostatic Neoplasms 1Glioma 1Glioblastoma 1Breast Cancer Female 1Brain Neoplasms 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × abemaciclib × Clear all
NCT06585969 2026-02-12

DISCORDANT

Danish Breast Cancer Cooperative Group

Phase 3 Withdrawn
Breast

Breast Neoplasms

NCT04351230 2022-05-26

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Academic and Community Cancer Research United

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT04585724 2021-10-18

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Emory University

Phase 1 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Dana-Farber Cancer Institute

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT03988114 2019-09-06

proMONARCH

Eli Lilly and Company

Phase 4 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡